Table 1.
Baseline characteristics of patients with and without low-molecular-weight heparin prophylaxis
| Characteristic | Overall N = 1526 | No Prophylaxis N = 891 | Prophylaxis N = 635 | P-value |
|---|---|---|---|---|
| Age | 86.3 ± 4.6 | 86.5 ± 4.6 | 86.1 ± 4.4 | 0.075 |
| Sex | 0.298 | |||
| Female | 547 (35.8%) | 329 (36.9%) | 218 (34.3%) | |
| Male | 979 (64.2%) | 562 (63.1%) | 417 (65.7%) | |
| BMI (Kg/m2) | 0.924 | |||
| 18.5–28 | 753 (82.1%) | 465 (81.7%) | 288 (82.8%) | |
| < 18.5 | 104 (11.3%) | 66 (11.6%) | 38 (10.9%) | |
| ≥ 28 | 60 (6.5%) | 38 (6.7%) | 22 (6.3%) | |
| Cardiovascular disease | 1126 (73.8%) | 657 (73.7%) | 469 (73.9%) | 0.958 |
| Respiratory disease | 378 (24.8%) | 231 (25.9%) | 147 (23.1%) | 0.216 |
| Gastrointestinal Disease | 163 (10.7%) | 102 (11.4%) | 61 (9.6%) | 0.251 |
| Chronic kidney disease | 213 (14.0%) | 127 (14.3%) | 86 (13.5%) | 0.693 |
| Stroke | 359 (23.5%) | 211 (23.7%) | 148 (23.3%) | 0.865 |
| Metabolic syndrome | 503 (33.0%) | 282 (31.6%) | 221 (34.8%) | 0.196 |
| Hematological diseases | 44 (2.9%) | 26 (2.9%) | 18 (2.8%) | 0.924 |
| VTE history | 50 (3.3%) | 29 (3.3%) | 21 (3.3%) | 0.955 |
| Active cancer | 61 (4.0%) | 40 (4.5%) | 21 (3.3%) | 0.245 |
| Disease severity at admission | < 0.001 | |||
| Moderate | 904 (59.2%) | 568 (63.7%) | 336 (52.9%) | |
| Severe | 441 (28.9%) | 223 (25.0%) | 218 (34.3%) | |
| Critical | 181 (11.9%) | 100 (11.2%) | 81 (12.8%) | |
| PLT (*109/L) | 0.003 | |||
| 100–300 | 1202 (81.1%) | 708 (81.8%) | 494 (79.9%) | |
| ≥ 300 | 141 (9.5%) | 65 (7.5%) | 76 (12.3%) | |
| < 100 | 140 (9.4%) | 92 (10.6%) | 48 (7.8%) | |
| HGB (g/L) | 0.786 | |||
| ≥ 120 | 850 (57.3%) | 489 (56.4%) | 361 (58.5%) | |
| 90–120 | 515 (34.7%) | 310 (35.8%) | 205 (33.2%) | |
| 60–90 | 110 (7.4%) | 63 (7.3%) | 47 (7.6%) | |
| < 60 | 9 (0.6%) | 5 (0.6%) | 4 (0.6%) | |
| d-dimer (mg/L) | 0.296 | |||
| < 0.5 | 137 (9.9%) | 84 (10.6%) | 53 (8.9%) | |
| ≥ 0.5 | 1246 (90.1%) | 706 (89.4%) | 540 (91.1%) | |
| eGFR (mL/min/1.73m2) | 0.431 | |||
| ≥ 90 | 138 (9.0%) | 75 (8.4%) | 63 (9.9%) | |
| 60–89 | 847 (55.5%) | 493 (55.3%) | 354 (55.7%) | |
| 30–59 | 379 (24.8%) | 220 (24.7%) | 159 (25.0%) | |
| < 30 | 162 (10.6%) | 103 (11.6%) | 59 (9.3%) | |
| Antiviral drug | 274 (18.0%) | 113 (12.7%) | 161 (25.4%) | < 0.001 |
| Corticosteroids | 816 (53.5%) | 418 (46.9%) | 398 (62.7%) | < 0.001 |
| Anti-platelet drugs | 109 (7.1%) | 64 (7.2%) | 45 (7.1%) | 0.943 |
| VTE | 139 (9.1%) | 93 (10.4%) | 46 (7.2%) | 0.033 |
| Death | 445 (29.2%) | 258 (29.0%) | 187 (29.4%) | 0.835 |
| All bleeding | 107 (7.0%) | 67 (7.5%) | 40 (6.3%) | 0.357 |
| Minor bleeding | 70 (4.6%) | 48 (5.4%) | 22 (3.5%) | |
| CRNMB | 29 (1.9%) | 15 (1.7%) | 14 (2.2%) | |
| Major bleeding | 8 (0.5%) | 4 (0.4%) | 4 (0.6%) | |
| Length of stay (days) | 14 ± 9 | 13 ± 9 | 15 ± 10 | 0.010 |
BMI, body mass index; VTE, venous thromboembolism; PLT, platelet; HGB, hemoglobin; eGFR, estimated glomerular filtration rate; IU, International Unit; CRNMB, clinically relevant non major bleeding